independent medical providers review patient information and determine whether prescriptions are appropriate, and partner pharmacies fulfill prescriptions written by those providers
~15% average weight loss Common side effects: nausea, constipation, diarrhea Also shown to reduce cardiovascular and kidney disease risks in some patients Tirzepatide (Zepbound) A dual-action medication: GLP-1 + GIP Enhances insulin, appetite control, and fat metabolism Average weight loss: ~20% in clinical trials Weekly injection Similar GI side effects to semaglutide Retatrutide (Coming Soon) A triple-agonist: GLP-1 + GIP + glucagon receptor Early studies show weight loss approaching 25% Still in clinical trials
Any of these can be win-win, depending on needs and finances
Any sign of irritation warrants a reassessment of your routine and perhaps a visit with your dermatologist
If you want a broader overview before choosing a tracker, start with our best GLP-1 app guide and our full breakdown of how to track GLP-1 progress across different medications
This has guided clinicians in anticipating the risk for malignancy and management options (Table 7-1)
